Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Molecular Biology

Background:

• Tumor-specific immunotherapies offer targeted cancer treatment with reduced toxicity.
• Pattern recognition receptors like RIG-I can induce antitumor responses but face delivery and off-target challenges.
• Current limitations hinder the clinical translation of RIG-I-based immunotherapies.

Purpose of the Study:

• To develop a strategy for intracellular assembly of a RIG-I agonist on a tumor-specific RNA template.
• To overcome delivery issues and off-target effects of RIG-I agonists for cancer treatment.
• To utilize a superparamagnetic nanoparticle carrier for targeted delivery and image-guided therapy.

Main Methods:

• Conjugation of a single-stranded anti-miR-21 5'-triphosphate RIG-I agonist to dextran-coated nanoparticles (TTX).
• In vitro and in vivo testing in a B16-F10 melanoma mouse model.
• Magnetic resonance imaging (MRI) for visualizing nanoparticle delivery and therapeutic efficacy assessment.

Main Results:

• Demonstrated miRNA-21-dependent RIG-I signaling and apoptosis in melanoma cells.
• Inhibited tumor growth and induced immunity against tumor rechallenge in an animal model.
• Confirmed the ability of the nanoparticle system to initiate specific RIG-I signaling.

Conclusions:

• The template-driven approach facilitates RIG-I activation within tumor cells.
• Systemic delivery of RIG-I agonists via nanoparticles enhances antitumor immune responses.
• This strategy advances RIG-I as a clinically relevant target in oncology.